Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus LANTRISUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus LANTRISUL.
DIFICID vs LANTRISUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Lantrisul (sulfadimethoxine) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking folic acid synthesis and ultimately nucleic acid production in susceptible bacteria.
200 mg (tablet) orally twice daily for 10 days.
Intravenous: 3 mg/kg every 8 hours for 14 days, then 5 mg/kg every 12 hours for 14 days; oral: 800 mg (10 mg/kg) twice daily after intravenous phase.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Terminal elimination half-life is 18 hours (range 16-20 h). This supports once-daily dosing; steady-state achieved after 3-4 days.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Approximately 70% renal excretion as unchanged drug, 15% fecal elimination via biliary secretion, 10% metabolized to inactive glucuronide conjugate eliminated renally, 5% other minor pathways.
Category C
Category C
Antibiotic
Antibiotic